source
- Spyre shares plunge as rheumatoid arthritis trial of SPY072 falls short of internal targetSpyre Therapeutics reported that its antibody SPY072 did not meet the company’s internal criteria in a mid‑stage rheumatoid arthritis trial, despite showing some activity. The placebo‑controlled s…
- Vitruvias Therapeutics shuts down after recalling potentially superpotent thyroid tabletsVitruvias Therapeutics announced it is ceasing operations and has voluntarily recalled a batch of its generic thyroid tablets because the product may be superpotent. The recall covers 3,655 units…